SU5416 in Treating Patients With Malignant Mesothelioma
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant
mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to
the tumor.